The antiplatelet function of prasugrel and clopidogrel

The antiplatelet function of prasugrel and clopidogrel assessed by the light transmission aggregometry in patients with stable coronary artery disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031220254

Enrollment

100

Registered

2022-08-08

Start date

2022-08-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable coronary artery disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age is 20 years or older at the time of consent acquisition 2) Those who are judged by the doctor in charge to be DAPT indicated due to PCI schedule for stable coronary artery disease 3) Maintenance of aspirin (100 mg / day) as part of standard treatment 4) Those who have received sufficient explanation before participating in this research, and who have obtained sufficient understanding and voluntary written consent of the research subject

Exclusion criteria

Exclusion criteria: 1) Platelet count 2.5 times the normal upper limit. 4) Pregnant or lactating women 5) Contraindications for prasugrel, clopidogrel, or stent placement 6) In addition, those who are judged by the principal investigator to be inappropriate as research subjects

Design outcomes

Primary

Measure	Time frame
Platelet agglutination ability(NSR-2)	—

Secondary

Measure	Time frame
Platelet agglutination ability(maximum aggregation rate)	—

Contacts

Public ContactYuhei Kojima

Juntendo University Nerima Hospital

yu-kojima@juntendo.ac.jp+81-3-5923-3111

Outcome results